The ACTIV public-private partnership has prioritized, designed, and harmonized five adaptive master protocols for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical trials to test prioritized therapeutic candidates. Master protocols allow coordinated and efficient evaluation of multiple investigational agents as they become available, but within the same clinical trial structure, across multiple study sites. Adaptive protocols swiftly weed out experimental drugs that do not demonstrate effectiveness and identify those that do. Adaptive master protocols reduce administrative burden and cost, provide a flexible framework to rapidly identify drugs that work, and rapidly move additional experimental agents into the trial. The ACTIV-1 master protocol is evaluating the safety and efficacy of at least three immune modulators (initially infliximab, abatacept and cencicrivoroc when given as an add-on therapy to standard of care, which currently includes remdesivir, The different treatments will be assessed with respect to illness severity, recovery speed, mortality and hospital resource utilization. Dr. Powderly is the Principal investigator for ACTIV-1 and the purpose of this supplement is to provide funding support for him and his Administrative Coordinator. In his role, he will participate in regular conference calls with ACTIV and NCATS leadership as well as leading weekly protocol team calls and regular calls with local PIs. He will review all safety events and other study end-points and present regular reports to the DSMB. He will also coordinate the reporting of the results and the writing of study manuscripts.
The ACTIV-1 master protocol is evaluating the safety and efficacy of at least three immune modulators (initially infliximab, abatacept and cencicrivoroc when given as an add-on therapy to standard of care, that includes remdesivir, The different treatments will be assessed with respect to illness severity, recovery speed, mortality and hospital resource utilization. Dr. Powderly is the Principal investigator for ACTIV 1.
| Waqar, Saiama N; Boehmer, Leigh; Morgensztern, Daniel et al. (2018) Immunogenicity of Influenza Vaccination in Patients With Cancer. Am J Clin Oncol 41:248-253 |
| Duncavage, Eric J; Jacoby, Meagan A; Chang, Gue Su et al. (2018) Mutation Clearance after Transplantation for Myelodysplastic Syndrome. N Engl J Med 379:1028-1041 |
| Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44 |
| Morris, Claudia R; Mauger, David T; Suh, Jung H et al. (2018) Glutathione and arginine levels: Predictors for acetaminophen-associated asthma exacerbation? J Allergy Clin Immunol 142:308-311.e9 |
| Shankar, Vikram A; Snyder-Warwick, Alison; Skolnick, Gary B et al. (2018) Incidence of Palatal Fistula at Time of Secondary Alveolar Cleft Reconstruction. Cleft Palate Craniofac J 55:999-1005 |
| Haller, Gabe; Zabriskie, Hannah; Spehar, Shelby et al. (2018) Lack of joint hypermobility increases the risk of surgery in adolescent idiopathic scoliosis. J Pediatr Orthop B 27:152-158 |
| Johnson, Eric K; Matkovich, Scot J; Nerbonne, Jeanne M (2018) Regional Differences in mRNA and lncRNA Expression Profiles in Non-Failing Human Atria and Ventricles. Sci Rep 8:13919 |
| Schindler, Suzanne E; Gray, Julia D; Gordon, Brian A et al. (2018) Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement 14:1460-1469 |
| Luke, Douglas A; Sarli, Cathy C; Suiter, Amy M et al. (2018) The Translational Science Benefits Model: A New Framework for Assessing the Health and Societal Benefits of Clinical and Translational Sciences. Clin Transl Sci 11:77-84 |
| Ban, Norimitsu; Lee, Tae Jun; Sene, Abdoulaye et al. (2018) Disrupted cholesterol metabolism promotes age-related photoreceptor neurodegeneration. J Lipid Res 59:1414-1423 |
Showing the most recent 10 out of 416 publications
